1
|
Della-Felice F, de Andrade Bartolomeu A, Pilli RA. The phosphate ester group in secondary metabolites. Nat Prod Rep 2022; 39:1066-1107. [PMID: 35420073 DOI: 10.1039/d1np00078k] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Covering: 2000 to mid-2021The phosphate ester is a versatile, widespread functional group involved in a plethora of biological activities. Its presence in secondary metabolites, however, is relatively rare compared to other functionalities and thus is part of a rather unexplored chemical space. Herein, the chemistry of secondary metabolites containing the phosphate ester group is discussed. The text emphasizes their structural diversity, biological and pharmacological profiles, and synthetic approaches employed in the phosphorylation step during total synthesis campaigns, covering the literature from 2000 to mid-2021.
Collapse
Affiliation(s)
- Franco Della-Felice
- Institute of Chemistry, University of Campinas (UNICAMP), P.O. Box 6154, CEP 13083-970 Campinas, Sao Paulo, Brazil.,Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain.
| | | | - Ronaldo Aloise Pilli
- Institute of Chemistry, University of Campinas (UNICAMP), P.O. Box 6154, CEP 13083-970 Campinas, Sao Paulo, Brazil
| |
Collapse
|
2
|
Shuto S. [Medicinal Chemical Studies Based on the Theoretical Design of Bioactive Compounds]. YAKUGAKU ZASSHI 2020; 140:329-344. [PMID: 32115550 DOI: 10.1248/yakushi.19-00208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
I have engaged in medicinal chemical studies based on the theoretical design of bioactive compounds. First, I present a three-dimensional structural diversity-oriented conformational restriction strategy for developing bioactive compounds based on the characteristic steric and stereoelectronic features of cyclopropane. Using this strategy, various biologically active small molecule compounds, such as receptor agonists/antagonists and enzyme inhibitors, were effectively developed. The strategy was also applied to develop versatile peptidomimetics and membrane-permeable cyclic peptides. Next, studies on Ca2+-mobilizing second messengers, cyclic ADP-ribose (cADPR) and myo-inositol trisphosphates (IP3), are described. In these studies, stable equivalents of cADPR were developed, since biological studies of cADPR have been limited due to its instability. Various potent IP3 receptor ligands, which were designed using the d-glucose structure as a bioisostere of the myo-inositol moiety of IP3, have been identified. Organic chemistry studies have also been extensively performed, because excellent organic chemistry is essential for promoting high-level medicinal chemical studies. For examples, new methods for the synthesis of chiral cyclopropanes, new radical reactions with silicon tethers, and kinetic anomeric effect-dependent stereoselective glycosidations have been developed.
Collapse
Affiliation(s)
- Satoshi Shuto
- Faculty of Pharmaceutical Sciences, Hokkaido University
| |
Collapse
|
3
|
Mills SJ, Rossi AM, Konieczny V, Bakowski D, Taylor CW, Potter BVL. d- chiro-Inositol Ribophostin: A Highly Potent Agonist of d- myo-Inositol 1,4,5-Trisphosphate Receptors: Synthesis and Biological Activities. J Med Chem 2020; 63:3238-3251. [PMID: 32052631 PMCID: PMC7104261 DOI: 10.1021/acs.jmedchem.9b01986] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Analogues
of the Ca2+-releasing intracellular messenger d-myo-inositol 1,4,5-trisphosphate [1, Ins(1,4,5)P3] are important synthetic targets. Replacement
of the α-glucopyranosyl motif in the natural product mimic adenophostin 2 by d-chiro-inositol in d-chiro-inositol adenophostin 4 increased
the potency. Similar modification of the non-nucleotide Ins(1,4,5)P3 mimic ribophostin 6 may increase the activity. d-chiro-Inositol ribophostin 10 was synthesized by coupling as building blocks suitably protected
ribose 12 with l-(+)-3-O-trifluoromethylsulfonyl-6-O-p-methoxybenzyl-1,2:4,5-di-O-isopropylidene-myo-inositol 11. Separable
diastereoisomeric 3-O-camphanate esters of (±)-6-O-p-methoxy-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol allowed the preparation
of 11. Selective trans-isopropylidene
deprotection in coupled 13, then monobenzylation gave
separable regioisomers 15 and 16. p-Methoxybenzyl group deprotection of 16, phosphitylation/oxidation,
then deprotection afforded 10, which was a full agonist
in Ca2+-release assays; its potency and binding affinity
for Ins(1,4,5)P3R were similar to those of adenophostin.
Both 4 and 10 elicited a store-operated
Ca2+ current ICRAC in patch-clamped cells, unlike
Ins(1,4,5)P3 consistent with resistance to metabolism. d-chiro-Inositol ribophostin is the most potent
small-molecule Ins(1,4,5)P3 receptor agonist without a
nucleobase yet synthesized.
Collapse
Affiliation(s)
- Stephen J Mills
- Drug Discovery & Medicinal Chemistry, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
| | - Ana M Rossi
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, United Kingdom
| | - Vera Konieczny
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, United Kingdom
| | - Daniel Bakowski
- Centre of Integrative Physiology, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom
| | - Colin W Taylor
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, United Kingdom
| | - Barry V L Potter
- Drug Discovery & Medicinal Chemistry, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
| |
Collapse
|
4
|
Someya H, Itoh T, Aoki S. Synthesis of Disaccharide Nucleosides Utilizing the Temporary Protection of the 2',3'-cis-Diol of Ribonucleosides by a Boronic Ester. Molecules 2017; 22:E1650. [PMID: 28974027 PMCID: PMC6151833 DOI: 10.3390/molecules22101650] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 09/24/2017] [Accepted: 09/29/2017] [Indexed: 11/16/2022] Open
Abstract
Disaccharide nucleosides are an important class of natural compounds that have a variety of biological activities. In this study, we report on the synthesis of disaccharide nucleosides utilizing the temporary protection of the 2',3'-cis-diol of ribonucleosides, such as adenosine, guanosine, uridine, 5-metyluridine, 5-fluorouridine and cytidine, by a boronic ester. The temporary protection of the above ribonucleosides permits the regioselective O-glycosylation of the 5'-hydroxyl group with thioglycosides using a p-toluenesulfenyl chloride (p-TolSCl)/silver triflate (AgOTf) promoter system to afford the corresponding disaccharide nucleosides in fairly good chemical yields. The formation of a boronic ester prepared from uridine and 4-(trifluoromethyl)phenylboronic acid was examined by ¹H, 11B and 19F NMR spectroscopy.
Collapse
Affiliation(s)
- Hidehisa Someya
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
| | - Taiki Itoh
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
- Imaging Frontier Center, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
| |
Collapse
|
5
|
Vibhute AM, Konieczny V, Taylor CW, Sureshan KM. Triazolophostins: a library of novel and potent agonists of IP3 receptors. Org Biomol Chem 2016; 13:6698-710. [PMID: 25869535 PMCID: PMC4533600 DOI: 10.1039/c5ob00440c] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
IP3R initiate most cellular Ca2+ signaling. AdA is the most potent agonist of IP3R. The structural complexity of AdA makes synthesis of its analogs cumbersome. We report an easy method for generating a library of potent triazole-based analogs of AdA, triazolophostins, which are the most potent AdA analogs devoid of a nucleobase.
IP3 receptors are channels that mediate the release of Ca2+ from the intracellular stores of cells stimulated by hormones or neurotransmitters. Adenophostin A (AdA) is the most potent agonist of IP3 receptors, with the β-anomeric adenine contributing to the increased potency. The potency of AdA and its stability towards the enzymes that degrade IP3 have aroused interest in AdA analogs for biological studies. The complex structure of AdA poses problems that have necessitated optimization of synthetic conditions for each analog. Such lengthy one-at-a-time syntheses limit access to AdA analogs. We have addressed this problem by synthesizing a library of triazole-based AdA analogs, triazolophostins, by employing click chemistry. An advanced intermediate having all the necessary phosphates and a β-azide at the anomeric position was reacted with various alkynes under Cu(i) catalysis to yield triazoles, which upon deprotection gave triazolophostins. All eleven triazolophostins synthesized are more potent than IP3 and some are equipotent with AdA in functional analyses of IP3 receptors. We show that a triazole ring can replace adenine without compromising the potency of AdA and provide facile routes to novel AdA analogs.
Collapse
Affiliation(s)
- Amol M Vibhute
- School of Chemistry, Indian Institute of Science Education and Research, Thiruvananthapuram, Kerala-695016, India.
| | | | | | | |
Collapse
|
6
|
Sureshan KM, Riley AM, Thomas MP, Tovey SC, Taylor CW, Potter BVL. Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A. J Med Chem 2012; 55:1706-20. [PMID: 22248345 PMCID: PMC3285137 DOI: 10.1021/jm201571p] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Although adenophostin A (AdA), the most potent agonist
of d-myo-inositol 1,4,5-trisphosphate receptors
(IP3R), is thought to mimic IP3, the relative
roles
of the different phosphate groups and the adenosine motif have not
been established. We synthesized all three possible bisphosphate analogues
of AdA and glucose 3,4-bisphosphate (7, AdA lacking the
2′-AMP). 2′-Dephospho-AdA (6) was prepared
via a novel regioselective dephosphorylation strategy. Assessment
of the abilities of these bisphosphates to stimulate intracellular
Ca2+ release using recombinant rat type 1 IP3R (IP3R1) revealed that 6, a mimic of Ins(4,5)P2, is only 4-fold less potent than IP3, while 7 is some 400-fold weaker and even 3″-dephospho-AdA
(5) is measurably active, despite missing one of the
vicinal bisphosphate groups normally thought to be crucial for IP3-like activity. Compound 6 is the most potent
bisphosphate yet discovered with activity at IP3R. Thus,
adenosine has a direct role independent of the 2′-phosphate
group in contributing toward the potency of adenophostins, the vicinal
bisphosphate motif is not essential for activity at the IP3R, as always thought, and it is possible to design potent agonists
with just two of the three phosphates. A model with a possible adenine–R504
interaction supports the activity of 5 and 6 and also allows a reappraisal of the unexpected activity previously
reported for the AdA regioisomer 2″-phospho-3″-dephospho-AdA 40.
Collapse
Affiliation(s)
- Kana M Sureshan
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
| | | | | | | | | | | |
Collapse
|
7
|
Cipolla L, Redaelli C, Granucci F, Zampella G, Zaza A, Chisci R, Nicotra F. Straightforward synthesis of novel Akt inhibitors based on a glucose scaffold. Carbohydr Res 2010; 345:1291-8. [DOI: 10.1016/j.carres.2009.12.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Revised: 11/26/2009] [Accepted: 12/13/2009] [Indexed: 02/02/2023]
|
8
|
Rossi AM, Riley AM, Potter BV, Taylor CW. Adenophostins. CURRENT TOPICS IN MEMBRANES 2010; 66:209-33. [DOI: 10.1016/s1063-5823(10)66010-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
|
9
|
Benito D, Isabel Matheu M, Morère A, Díaz Y, Castillón S. Designing an effective approach for obtaining methylenecarboxylate analogues of adenophostin A. Preliminary results. Carbohydr Res 2009; 344:2559-67. [DOI: 10.1016/j.carres.2009.09.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 09/16/2009] [Accepted: 09/27/2009] [Indexed: 11/29/2022]
|
10
|
Benito D, Matheu MI, Morère A, Díaz Y, Castillón S. Towards the preparation of 2″-deoxy-2″-fluoro-adenophostin A. Study of the glycosylation reaction. Tetrahedron 2008. [DOI: 10.1016/j.tet.2008.09.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Sureshan KM, Trusselle M, Tovey SC, Taylor CW, Potter BVL. 2-Position Base-Modified Analogues of Adenophostin A as High-Affinity Agonists of the d-myo-Inositol Trisphosphate Receptor: In Vitro Evaluation and Molecular Modeling. J Org Chem 2008; 73:1682-92. [DOI: 10.1021/jo702617c] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Kana M. Sureshan
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, U.K
| | - Melanie Trusselle
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, U.K
| | - Stephen C. Tovey
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, U.K
| | - Colin W. Taylor
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, U.K
| | - Barry V. L. Potter
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge CB2 1PD, U.K
| |
Collapse
|
12
|
Fei Z, McDonald FE. Stereo- and regioselective glycosylations to the bis-C-arylglycoside of kidamycin. Org Lett 2007; 9:3547-50. [PMID: 17691798 PMCID: PMC4604443 DOI: 10.1021/ol7014219] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In explorations toward the total synthesis of the antitumor anthrapyran natural product kidamycin, the regioselective introduction of aminosugars angolosamine and vancosamine as C-arylglycosides has been accomplished onto hydroxylated anthrapyran aglycones. Specifically, the 9,11-dihydroxylated anthrapyran A undergoes sequential glycosylations with angolosamine synthon B and vancosamine synthon C to regio- and stereoselectively afford bis-C-glycoside D corresponding to the C-glycoside pattern of kidamycin.
Collapse
Affiliation(s)
- ZhongBo Fei
- Department of Chemistry, Emory University, Atlanta, GA 30322
| | | |
Collapse
|
13
|
Bérubé M, Poirier D. Chemical synthesis and in vitro biological evaluation of a phosphorylated bisubstrate inhibitor of type 3 17beta-hydroxysteroid dehydrogenase. J Enzyme Inhib Med Chem 2007; 22:201-11. [PMID: 17518347 DOI: 10.1080/14756360601051423] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Type 3 17beta-hydroxysteroid dehydrogenase (17beta-HSD) catalyzes the last step in the biosynthesis of the potent androgen testosterone (T) by selectively reducing the C17 ketone of 4-androstene-3,17-dione (delta4-dione), with NADPH as cofactor. This enzyme is thus an interesting therapeutic target for androgen-sensitive diseases. Using an efficient convergent chemical approach we synthesized a phosphorylated version of the best delta4-dione/adenosine hybrid inhibitor of type 3 17beta-HSD previously reported. An appropriately protected C2' phosphorylated adenosine was first prepared and linked by esterification to the steroid delta4-dione bearing an alkyl spacer. After three deprotection steps, the phosphorylated bisubstrate inhibitor was obtained. The inhibitory potency of this compound was evaluated on homogenated HEK-293 cells overexpressing type 3 17beta-HSD and compared to the best non-phosphorylated bisubstrate inhibitor. Unexpectedly, the phosphorylated derivative was slightly less potent than the non-phosphorylated bisubstrate inhibitor of type 3 17beta-HSD. Two hypotheses are discussed to explain this result: 1) the phosphorylated adenosine moiety does not interact optimally with the cofactor-binding site and 2) the bisubstrate inhibitors, phosphorylated or not, interact only with the substrate-binding site of type 3 17beta-HSD.
Collapse
Affiliation(s)
- Marie Bérubé
- Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, CHUQ-Pavillon CHUL and Université Laval, Québec G1V 4G2, Canada
| | | |
Collapse
|
14
|
Chrétien F, Roussel F, Hilly M, Mauger J, Chapleur Y. New Sugar‐Based Permeant Analogs of D‐ Myo ‐Inositol 1,4,5‐Trisphosphate Mimicking the Effect of Vasopressin: Synthesis and Biologic Evaluation*. J Carbohydr Chem 2005. [DOI: 10.1081/car-200068070] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Terauchi M, Yahiro Y, Abe H, Ichikawa S, Tovey SC, Dedos SG, Taylor CW, Potter BV, Matsuda A, Shuto S. Synthesis of 4,8-anhydro-d-glycero-d-ido-nonanitol 1,6,7-trisphosphate as a novel IP3 receptor ligand using a stereoselective radical cyclization reaction based on a conformational restriction strategy. Tetrahedron 2005. [DOI: 10.1016/j.tet.2005.02.025] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Rosenberg HJ, Riley AM, Laude AJ, Taylor CW, Potter BVL. Synthesis and Ca2+-Mobilizing Activity of Purine-Modified Mimics of Adenophostin A: A Model for the Adenophostin−Ins(1,4,5)P3Receptor Interaction. J Med Chem 2003; 46:4860-71. [PMID: 14584937 DOI: 10.1021/jm030883f] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The synthesis of a series of adenophostin A analogues modified at C-6 and C-2 of adenine is described. The target compounds were synthesized by a convergent route involving a modified Vorbrüggen condensation of either 6-chloropurine or 2,6-dichloropurine with a protected disaccharide, yielding two versatile intermediates capable of undergoing substitution with a range of nucleophiles. The new analogues showed a range of abilities to mobilize Ca(2+) from the intracellular stores of permeabilized hepatocytes and are among the first totally synthetic compounds to approach the activity of adenophostin A. In agreement with the biological results, docking studies of adenophostin A using the recently reported X-ray crystal structure of the type 1 Ins(1,4,5)P(3) receptor binding core suggested that, in likely binding modes of adenophostin A, the area around N(6) may be relatively open, identifying this region of the adenophostin A molecule as a promising target for further elaboration. The docking results also point to specific interactions involving residues within the binding domain of the Ins(1,4,5)P(3) receptor that may be involved in the molecular recognition of the adenophostins.
Collapse
Affiliation(s)
- Heidi J Rosenberg
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK
| | | | | | | | | |
Collapse
|
17
|
Riley AM, Jenkins DJ, Marwood RD, Potter BVL. Synthesis of glucopyranoside-based ligands for D-myo-inositol 1,4,5-trisphosphate receptors. Carbohydr Res 2002; 337:1067-82. [PMID: 12062522 DOI: 10.1016/s0008-6215(02)00103-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Adenophostins A and B are naturally occurring glyconucleotides that interact potently with receptors for D-myo-inositol 1,4,5-trisphosphate, an important second messenger molecule in most cell types. Here we describe the design and synthesis of glucopyranoside-based analogues of adenophostin A lacking the adenine component. The key synthetic strategy involves glycosylation of selectively protected alcohols, derived from methyl beta-D-ribofuranoside or 1,4-anhydroerythritol, using glycosyl donors synthesised from 2,6-di-O-benzyl-D-glucopyranose derivatives. Further elaboration and deprotection of the coupled products gave two trisphosphate analogues; methyl 3-O-alpha-D-glucopyranosyl-beta-D-ribofuranoside 2,3',4'-trisphosphate ("ribophostin") and (3'S,4'R)-3'-hydroxytetrahydrofuran-4'-yl alpha-D-glucopyranoside 3,4,3'-trisphosphosphate ("furanophostin"). The route to furanophostin was further modified to give (3'S,4'R)-3'-hydroxytetrahydrofuran-4'-yl alpha-D-glucopyranoside 3'-phosphate 3,4-bisphosphorothioate, the first phosphorothioate-containing adenophostin analogue.
Collapse
Affiliation(s)
- Andrew M Riley
- Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, UK
| | | | | | | |
Collapse
|